Cited by 121Alzheimer's disease research and treatmentsCalpain Protease Function and RegulationDementia and Cognitive Impairment Research

Calpain Activation in Alzheimer's Model Mice Is an Artifact of APP and Presenilin Overexpression

Open access
Saito, Takashi, Matsuba, Yukio, Yamazaki, Naomi, Hashimoto, Shoko, Saido, Takaomi C.·2016·The Journal of Neuroscience

Abstract

Intraneuronal calcium stimulates the calpain-dependent conversion of p35 to p25, a CDK5 activator. It is widely believed that amyloid β peptide (Aβ) induces this conversion that, in turn, has an essential role in Alzheimer's disease pathogenesis. However,in vivo studies on p25 generation used transgenic mice overexpressing mutant amyloid precursor protein (APP) and presenilin (PS). Here, using single App knock-in mice, we show that p25 generation is an artifact caused by membrane protein overexpression. We show that massive Aβ 42 accumulation without overexpression of APP or presenilin does not produce p25, whereas p25 generation occurred with APP/PS overexpression and in postmortem mouse brain. We further support this finding using mice deficient for calpastatin, the sole calpain-specific inhibitor protein. Thus, the intracerebral environment of the APP/PS mouse brain and postmortem brain is an unphysiological state. SIGNIFICANCE STATEMENT We recently estimated using single App knock-in mice that accumulate amyloid β peptide without transgene overexpression that 60% of the phenotypes observed in Alzheimer's model mice overexpressing mutant amyloid precursor protein (APP) or APP and presenilin are artifacts (Saito et al., 2014). The current study further supports this estimate by invalidating key results from papers that were published in Cell. These findings suggest that more than 3000 publications based on APP and APP/PS overexpression must be reevaluated.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1523/jneurosci.1907-16.2016

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Parental lines rely on transgenic overexpression of familial AD or FTD mutations and do not fully recapitulate the slow accumulation of amyloid and tau in humans.

    “First, although 5XFAD;PS19 provides an experimentally tractable system for studying Aβ–tau interactions, parental lines rely on transgenic overexpression of familial AD or frontotemporal dementia (FTD) mutations and do not fully recapitulate the slow accumulation of amyloid and tau in humans. 70 , 71”

    From Unique transcriptomic alterations in 5XFAD;PS19 mouse model identify glial lipid dysregulation and coordinated microglial–oligodendrocyte responses (2026) · cites this paper as [71]

    The Introduction (page not specified in our copy) identifies 5XFAD mice as transgenic mice overexpressing APP and presenilin with five familial AD-associated mutations. The Results and Discussion describe artifacts of APP overexpression that limit these models' resemblance to AD. The paper does not identify PS19 or an FTD mutation, or assess whether the parental lines reproduce the slow accumulation of both amyloid and tau in humans. (LLM, conf=0.88)

    Experimental — accuracy not yet measured
  • Both AppNL-F and AppNL-G-F models express human APP at physiological levels.

    “Both models express human APP at physiological levels.”

    From Integrated analysis of behavioral, epigenetic, and gut microbiome analyses in AppNL-G-F, AppNL-F, and wild type mice (2021) · cites this paper as [24]

    The Results (page not provided) describe mutant humanized App knock-in mice that do not overexpress APP, and the Materials and Methods identify the mice studied as AppNL-F/NL-F. This supports physiological rather than elevated APP expression for AppNL-F, but our copy does not identify AppNL-G-F or establish its APP expression level. (LLM, conf=0.86)

    Experimental — accuracy not yet measured
  • The AppNL-G-F and AppNL-F show neuropathology and hippocampus-dependent cognitive impairments at 6 or 18 months, respectively.

    “The AppNL-G-F and AppNL-F show neuropathology and hippocampus-dependent cognitive impairments at 6 or 18 months, respectively.”

    From Integrated analysis of behavioral, epigenetic, and gut microbiome analyses in AppNL-G-F, AppNL-F, and wild type mice (2021) · cites this paper as [24]

    The Results (pp. 9933–9936) report massive Aβ deposition in 24-month-old AppNL-F mice, supporting a neuropathology finding for that model. The paper does not report the claimed hippocampus-dependent cognitive impairments, the 6- and 18-month ages, or a finding for AppNL-G-F. (LLM, conf=0.86)

    Experimental — accuracy not yet measured
  • APP overexpression was recently suggested to be the underlying cause of two prominent AD phenotypes, rather than a downstream response to Aβ as was initially suggested based on studies using transgenic mice.

    “Furthermore, APP overexpression was recently suggested to be the underlying cause of two prominent AD phenotypes, rather than a downstream response to Aβ as was initially suggested based on studies using transgenic mice, calling into question whether this may also be the case for other interpreted examples of downstream AD pathology observed in transgenic mouse models [130].”

    From Alzheimer's disease: experimental models and reality (2017) · cites this paper as [130]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 25 · Cited by 121

Authors
Saito, T., Matsuba, Y., Yamazaki, N., Hashimoto, S., & Saido, T. C.
Affiliations
RIKEN Center for Brain Science (JP)
Venue
The Journal of Neuroscience
Published
2016-09-21
Volume
36
Issue
38
Pages
9933-9936
ISSN
  • 0270-6474 (ISSN-L)
  • 1529-2401
OpenAlex
W2521074193
Cited by
121
References
25
Citations by year
2026: 7 · 2025: 9 · 2024: 7 · 2023: 8 · 2022: 10 · 2021: 19 · 2020: 11 · 2019: 12 · 2018: 23 · 2017: 13 · 2016: 2
FWCI
13.31
Type
journal article
Language
en
Open access
Locations
  • Journal of Neuroscience (publishedVersion, cc-by)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Japan Agency for Medical Research and Development
  • Ministry of Education, Culture, Sports, Science and Technology
  • Japan Society for the Promotion of Science (26290019)
  • Japan Science and Technology Agency
  • Precursory Research for Embryonic Science and Technology
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Calpain Protease Function and Regulation
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
calpain activation, cyclin-dependent kinase 5, amyloid-beta, amyloid precursor protein, presenilin, calpastatin, experimental artifacts, postmortem brain
MeSH terms
Alzheimer Disease, Animals, Brain, Calcium-Binding Proteins, Disease Models, Animal, Gene Expression Regulation, Humans, Membrane Proteins, Mice, Inbred C57BL, Mice, Transgenic, Mutation, Peptide Fragments, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Mice, Presenilin-1, NAV1.1 Voltage-Gated Sodium Channel

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review